Literature DB >> 6153252

Macular lesions in blacks with the presumed ocular histoplasmosis syndrome.

M A Baskin, L M Jampol, F U Huamonte, M F Rabb, C M Vygantas, G Wyhinny.   

Abstract

Six black patients had fundus lesions diagnostic of the presumed ocular histoplasmosis syndrome. All patients had peripapillary changes or peripheral punched-out chorioretinal lesions, or both. Five of the six had macular subretinal neovascularization, disciform scarring, or an atrophic macular lesion, and one patient had a macular hole; four of five patients tested had a positive histoplasmin skin test. The macular involvement was bilateral in three of the six cases. HLA B-7 was present in one of four patients who had HLA typing. Macular involvement can occur in blacks with the presumed ocular histoplasmosis syndrome.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6153252     DOI: 10.1016/0002-9394(80)90233-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Aetiological study of the presumed ocular histoplasmosis syndrome in the Netherlands.

Authors:  J V Ongkosuwito; L M Kortbeek; A Van der Lelij; E Molicka; A Kijlstra; M D de Smet; M S Suttorp-Schulten
Journal:  Br J Ophthalmol       Date:  1999-05       Impact factor: 4.638

Review 2.  Macular holes.

Authors:  T Barrie
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

Review 3.  Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Susan J Keam; Lesley J Scott; Monique P Curran
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Spontaneous closure of macular holes secondary to posterior uveitis: case series and a literature review.

Authors:  Nicolas Bonnin; Pierre-Loïc Cornut; Florian Chaise; Elodie Labeille; Helene Janin Manificat; Audrey Feldman; Laurent Perard; Franck Bacin; Frédéric Chiambaretta; Carole Burillon
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-02-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.